Related Experiment Videos
[Placental circulation in simultaneous beta-stimulation using hexoprenaline and beta-1 blockade with celiprolol]
Zeitschrift Fur Geburtshilfe Und Perinatologie
|January 1, 1987
Summary
Hexoprenalin therapy alone did not significantly alter cardiovascular parameters or placenta perfusion. Adding Celiprolol or placebo did not further change placenta perfusion, questioning the need for additional beta-mimetic agents.
Area of Science:
- Pharmacology
- Obstetrics
- Cardiovascular Physiology
Background:
- Hexoprenalin is a beta-mimetic agent used in obstetric therapy.
- The cardiovascular effects and impact on placental perfusion of Hexoprenalin, alone or in combination with other agents, require further investigation.
Purpose of the Study:
- To evaluate the effect of additional Celiprolol or placebo administration on placental perfusion during Hexoprenalin therapy.
- To assess the necessity of combined beta-mimetic and beta-blocking agent therapy in this context.
Main Methods:
- A therapy involving Hexoprenalin at 0.3 microgram/min was administered.
- Celiprolol (3 x 100 micrograms orally) or a placebo was given as an additional treatment.
- Placental perfusion and cardiovascular parameters were monitored.
Main Results:
- Hexoprenalin alone did not significantly change cardiovascular parameters.
- The addition of Celiprolol or placebo to Hexoprenalin therapy did not significantly alter placental perfusion.
- The study suggests Hexoprenalin alone may not necessitate additional beta-mimetic agents.
Conclusions:
- Combined therapy with Hexoprenalin and Celiprolol or placebo does not significantly impact placental perfusion.
- The necessity of additional beta-mimetic agents alongside Hexoprenalin is questionable given its isolated effects.
- Findings are specific to the studied doses and agents and not transferable to other combinations.